Clinical trial NCT06598202: Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
Official title: An Exploratory Study on the Use of Intranasal Administration of Small Extracellular Vesicles for the Treatment of Amyotrophic Lateral Sclerosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Amyotrophic Lateral Sclerosis
Keywords: Neurodegenerative diseases
Inflammation
Motor neuron degeneration
Exosomes
Small extracellular vesicles
Lead sponsor: Xuanwu Hospital, Beijing
Sponsor class: OTHER
Collaborators: name: Shengqi Medical Technology (Guangzhou) Co., Ltd.
name: Viyun (Xiamen) Biomedical Research Institute Co., Ltd.
First posted: 2024-09-19
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis.

Detailed description: This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The study will consist of two parts: Part 1 will be a dose-escalation study, and Part 2 will be an expanded safety study based on the findings from Part 1.

A traditional 3+3 dose-escalation design will be implemented in Part 1. Cohort 1 will receive low-dose; Cohort 2 will receive middle-dose; and Cohort 3 will receive high-dose. (Cohort 1 to Cohort 3 will receive a dose of 1 mL per nostril, administered once daily, twice a week, for a total of two weeks.) If no dose-limiting toxicities (DLTs) are observed for 2 weeks after the administration of the first nasal drop, a new cohort will be enrolled at the next planned dose level. If DLTs are observed in one participant in the cohort, an additional three participants will be treated at the same dose level. Dose escalation will be stopped if DLTs are observed in more than 33% of the participants.

In Part 2, 20 subjects will be randomized in a 1:1 ratio \[exosome (n=10) or exosome placebo (n=10)\]. The dose level will be determined by the primary researcher based on the findings from Part 1.

Eligibility criteria: Inclusion Criteria:

* Age: 18-80 years, inclusion of both genders;
* Disease duration: ≥6 months and ≤2 years (counted from the onset of any ALS symptoms);
* Subjects must meet the El Escorial revised criteria (2000) for the diagnosis of ALS, with a diagnosis of Definite ALS, Probable ALS, Probable laboratory-supported ALS, or Possible ALS;
* A score of ≥2 on each item of the revised ALS Functional Rating Scale (ALSFRS-R), with a score of 4 for items related to dyspnea, orthopnea, and respiratory insufficiency;
* BMI: Between 18 and 30 kg/m²;
* Subjects must have a baseline forced vital capacity percentage (%FVC) ≥70%;
* Allowed concomitant treatments: Oral administration of riluzole/edaravone at standard doses for ≥30 days; regular intravenous edaravone with planned sequential oral treatment. During the trial and follow-up period, the dosage and type of concomitant medications must remain unchanged;
* Subjects of childbearing potential must use appropriate and effective contraception from 2 weeks prior to trial enrollment until the end of the follow-up period;
* The subject or legal representative must be able to sign an informed consent form and comply with the study requirements for medication administration and follow-up.

Exclusion Criteria:

* Diagnosed as non-ALS based on clinical presentation and available clinical examinations (e.g., neurophysiological tests, MRI, or other imaging, laboratory tests);
* Abnormal nasal anatomy, nasal cavity damage, severe rhinitis, or nasal disease affecting the administration of the study drug;
* Requires nasal insertion of a gastric tube;
* Peripheral venous hemoglobin (HGB) \< 100 g/L, absolute neutrophil count (NEUT) \< 1.5×10\^9/L, platelet count (PLT) \< 100×10\^9/L, white blood cell count (WBC) \< 4.0×10\^9/L or ≥ 12×10\^9/L, serum albumin \< 30 g/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 3× the upper limit of normal (ULN);
* Severe renal insufficiency: Glomerular Filtration Rate (GFR) \< 30 mL/min (Cockcroft-Gault formula), or other known severe renal diseases;
* Positive for hepatitis B surface antigen, e antigen, e antibody, or core antibody combined with positive hepatitis B virus DNA; positive for hepatitis C virus antibody; positive syphilis serum antibody; or positive for HIV antibody;
* History of acute myocardial infarction or interventional treatment within the last 6 months, or heart failure (classified as NYHA III-IV);
* Presence of severe localized or systemic infection, immunodeficiency, or currently taking immunosuppressants;
* Concurrent severe systemic diseases such as immunodeficiency diseases, coagulation disorders, or malignancies;
* Vaccination within 1 month prior to the first administration or during the study until the end of follow-up;
* Known allergy to the drugs used in this study or similar drugs;
* Participation in another study and administration of an investigational product within the last 3 months;
* Contraindications to MRI (e.g., presence of metal implants) or inability to tolerate MRI (e.g., claustrophobia);
* Pregnant or breastfeeding women, or women of childbearing potential who cannot or are unwilling to use appropriate contraception;
* Unwillingness or inability to comply with the procedures required by the protocol;
* Any other conditions deemed unsuitable for inclusion by the investigators.

Primary outcomes:
measure: Number of participants who experienced dose-limiting Toxicities (DLTs)
timeFrame: 24 hours, 4±1 Weeks
Secondary outcomes:
measure: Incidence of severe adverse events
timeFrame: 4±1 Weeks
measure: Change from baseline in ALS functional rating scale - revised
timeFrame: 4±1 Weeks, 12±1 Weeks, 24±1 Weeks
measure: Change from baseline in forced vital capacity to predicted value ratio (FVC% pred)
timeFrame: 4±1 Weeks, 24±1 Weeks
measure: Time to event (death, tracheostomy, and permanent assisted mechanical ventilation)
timeFrame: up to 24 Weeks
measure: Change from baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40).
timeFrame: 4±1 Weeks, 12±1 Weeks, 24±1 Weeks
measure: Change from baseline in the Edinburgh Cognitive and Behavioral ALS Screen (ECAS).
timeFrame: 12±1 Weeks, 24±1 Weeks
measure: Change from baseline in the Neurophysiological Index (NI) and Compound Muscle Action Potential (CMAP) score.
timeFrame: 12±1 weeks
measure: Change from baseline in the Rasch Overall ALS Disability Scale (ROADS).
timeFrame: 4±1 Weeks, 12±1 Weeks, 24±1 Weeks
measure: Change from baseline in the Medical Research Council (MRC) Scale.
timeFrame: 4±1 Weeks, 12±1 Weeks, 24±1 Weeks
measure: Change from baseline in the the Lower Motor Neuro Scale(LMNS).
timeFrame: 4±1 Weeks, 12±1 Weeks, 24±1 Weeks
Other outcomes:
measure: Change from baseline in the neuroimaging indices.
timeFrame: 24±1 weeks
measure: Change from baseline in the blood markers.
timeFrame: up to 24 weeks
Locations:
city: Beijing
country: China
facility: Xuanwu Hospital ,Capital Medical University
state: Beijing
Study officials:
affiliation: Xuanwu Hospital, Beijing
name: Junwei Hao, MD; PhD
role: PRINCIPAL_INVESTIGATOR
References: